Abstract
Background
Incidence of endometrial carcinoma, the most common malignancy of the female pelvis, has been steadily increasing during the last three decades. The prognosis for stage IVb cases with extra-abdominal metastases is extremely poor, with no current consensus regarding treatment. The aim of the present study was to examine the benefits of cytoreductive surgery for such cases.
Methods
Clinicopathological features of 33 stage IVb cases of endometrial carcinoma diagnosed during the 1991–2008 study period were retrospectively reviewed utilizing clinical records. Cytoreduction was conducted in 30 cases.
Results
The median progression-free survival (PFS) and overall survival (OS) of those patients with optimal cytoreduction of their disease (with residual masses ≤ 2 cm), were significantly better than those with suboptimal reduction (with residual masses > 2 cm), not only among the 15 stage IVb patients with only intra-abdominal metastasis (group I) (P = 0.0003 and 0.0007) but also among the 15 cases with extra-abdominal metastasis (group E) (P = 0.013 and 0.016). Multivariate Cox proportional-hazards analysis demonstrated that the adjusted hazard ratio (HR) for the maximum size of residual disease (>2 vs. ≤2 cm) was 10.4 [95% confidence interval (CI), 1.27–84.70, P = 0.030] in group I and 16.92 (95% CI, 1.41–203.09, P = 0.026) in group E.
Conclusions
This is the first demonstration that aggressive cytoreductive surgery for stage IVb endometrial carcinoma with extra-abdominal metastasis has a beneficial role. However, further investigation is still required to establish better standard therapy for stage IVb endometrial cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DiSaia PJ, Creasman WT. Clinical gynecologic oncology, 6th ed. Mosby, St. Louis; 2002.
Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVb endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78:85–91.
Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992;45:142–6.
Marino BD, Burke TW, Tornos C, Chuang L, Mitchell MF, Tortolero-Luna G, et al. Staging laparotomy for endometrial carcinoma: assessment of peritoneal spread. Gynecol Oncol. 1995;56:34–8.
Vardi JR, Tadros GH, Anselmo MT, Rafla SD. The value of exploratory laparotomy in patients with endometrial carcinoma according to the new International Federation of Gynecology and Obstetrics staging. Obstet Gynecol. 1992;80:204–8.
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–9.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.
Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T. The influence of cytoreductive surgery on survival and morbidity in Stage IVb endometrial cancer. Int J Gynecol Cancer. 2002;12:448–53.
Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol. 1997;67:56–60.
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer. 2009;19:431–46.
Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048–53.
Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, et al. Hellenic Co-operative Oncology Group. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol. 2008;110:87–92.
Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8:969–72.
Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol. 1994;52:237–40.
Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol. 2001;81:92–9.
Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002;12:454–8.
Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190–3.
Lambrou NC, Gómez-Marín O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol. 2004;93:653–8.
Acknowledgment
The authors would like to thank G. S. Buzard, CDCP, Michele Buzard, Kaplan University-Hagerstown, and Jonathan Mitchell, Virginia Technical University, for their constructive critiques and editing of our manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Ueda, Y., Enomoto, T., Miyatake, T. et al. Endometrial Carcinoma with Extra-abdominal Metastasis: Improved Prognosis Following Cytoreductive Surgery. Ann Surg Oncol 17, 1111–1117 (2010). https://doi.org/10.1245/s10434-009-0892-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-009-0892-8